The White House is expected to launch TrumpRx, its newly announced direct-to-consumer platform for pharmaceutical products, on Friday, backed by the recent pricing deals the Trump administration signed with leading drugmakers, according to MS Now.
Citing two White House officials, the media outlet reported that the Trump administration is ready to launch the site following a demonstration at South Court Auditorium of the Eisenhower Executive Office Building.
After reaching a drug pricing deal with Pfizer (PFE) in September, the White House unveiled TrumpRx to offer brand-name prescription medicines at sharply discounted prices for cash-paying customers.
As part of the deal, the New York-based pharma giant agreed to offer discounts ranging from 50% to 85% for some of its blockbuster medicines, including its arthritis drug Xeljanz, in exchange for a three-year tariff reprieve and additional investments in the U.S.
Several other pharma majors, including Eli Lilly (LLY), Novo Nordisk (NVO), AstraZeneca (AZN), EMD Serono of Germany’s Merck KGaA (MKGAF), and AbbVie (ABBV), also agreed to offer some of their products on TrumpRx following similar drug pricing deals with the administration.